Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
R3H domain-containing protein 4 (R3HDM4) is a protein encoded by the human R3HDM4 gene on chromosome 19[1][6][7]. It is predicted to enable nucleic acid binding and is localized to the nucleus[1][6]. The classical R3H domain is a conserved sequence motif present in proteins across eubacteria, plants, fungi, and animals, serving as a single-stranded DNA/RNA-binding domain typically found in combination with other functional domains[3][4]. While the R3H domain is structurally characterized in some proteins, the specific biological role of R3HDM4 in humans is not well-defined and there are no known disease associations, interacting drugs, or established use as a biomarker or therapeutic target[1][6][7]. The aliases “C19orf22” and “MGC16353” reflect previous nomenclature based on its chromosomal location and sequence identification[1]. R3HDM4 is primarily noted for its potential to bind nucleic acids through its R3H domain, but current literature does not support its involvement in pathophysiological processes or its recognition as a therapeutic target in clinical practice[1][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on R3H domain-containing protein 4 (R3HDM4).